Correspondence
Answer to the “Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure” correspondence
Respuesta a la carta «Tratamiento con glucocorticoides en pacientes con COVID-19 e insuficiencia cardíaca concurrente»
A. Salinas-Botrána,
, L.M. Pérez-Belmonteb,
, M. Méndez-Bailóna, en representación del grupo SEMI-COVID-19 Network
Autor para correspondencia
Autor para correspondencia
a Servicio de Medicina Interna, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria delHospital ClínicoSan Carlos (IdISSC),Madrid, Spain
b Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Málaga, Spain
Leído
1230
Vecesse ha leído el artículo
37
Total PDF
1193
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 3 | 0 | 3 |
| 2025 5 | 22 | 0 | 22 |
| 2025 4 | 15 | 0 | 15 |
| 2025 3 | 23 | 0 | 23 |
| 2025 2 | 22 | 0 | 22 |
| 2025 1 | 14 | 0 | 14 |
| 2024 12 | 21 | 0 | 21 |
| 2024 11 | 17 | 0 | 17 |
| 2024 10 | 32 | 0 | 32 |
| 2024 9 | 19 | 0 | 19 |
| 2024 8 | 21 | 0 | 21 |
| 2024 7 | 22 | 0 | 22 |
| 2024 6 | 15 | 0 | 15 |
| 2024 5 | 23 | 0 | 23 |
| 2024 4 | 21 | 0 | 21 |
| 2024 3 | 11 | 0 | 11 |
| 2024 2 | 11 | 0 | 11 |
| 2024 1 | 17 | 0 | 17 |
| 2023 12 | 16 | 0 | 16 |
| 2023 11 | 38 | 0 | 38 |
| 2023 10 | 25 | 0 | 25 |
| 2023 9 | 33 | 3 | 36 |
| 2023 8 | 23 | 0 | 23 |
| 2023 7 | 29 | 0 | 29 |
| 2023 6 | 30 | 0 | 30 |
| 2023 5 | 42 | 6 | 48 |
| 2023 4 | 28 | 0 | 28 |
| 2023 3 | 25 | 2 | 27 |
| 2023 2 | 22 | 0 | 22 |
| 2022 1 | 26 | 0 | 26 |
| 2022 12 | 31 | 1 | 32 |
| 2022 11 | 37 | 0 | 37 |
| 2022 10 | 32 | 2 | 34 |
| 2022 9 | 28 | 0 | 28 |
| 2022 8 | 32 | 3 | 35 |
| 2022 7 | 34 | 1 | 35 |
| 2022 6 | 53 | 0 | 53 |
| 2022 5 | 136 | 6 | 142 |
| 2022 4 | 39 | 7 | 46 |
| 2022 3 | 25 | 3 | 28 |
| 2022 2 | 55 | 3 | 58 |
| 2021 1 | 25 | 0 | 25 |
Mostrar todo
